WO1988008854A1 - Anticorps monoclonaux contre le carcinome des cellules renales - Google Patents

Anticorps monoclonaux contre le carcinome des cellules renales Download PDF

Info

Publication number
WO1988008854A1
WO1988008854A1 PCT/US1988/001511 US8801511W WO8808854A1 WO 1988008854 A1 WO1988008854 A1 WO 1988008854A1 US 8801511 W US8801511 W US 8801511W WO 8808854 A1 WO8808854 A1 WO 8808854A1
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
antibody
rcc
specific
group
Prior art date
Application number
PCT/US1988/001511
Other languages
English (en)
Inventor
Egbert Oosterwijk
Sven O. Warnaar
Original Assignee
Egbert Oosterwijk
Warnaar Sven O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egbert Oosterwijk, Warnaar Sven O filed Critical Egbert Oosterwijk
Publication of WO1988008854A1 publication Critical patent/WO1988008854A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/106—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from kidney or bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Imaging based on the detection of nuclear magnetic resonance (NMR) properties of tissues labeled with paramegnetic substance can also be employed.
  • Monoclonal antibodies may be used to deliver the paramagnetic substance to the RCC site and allow detection of tumor masses by NMR imaging.
  • a hybridoma producing an anti-T3 antibody can be fused with hybridoma producing antibody against the RCC antigen (preferably RC 38 or G250) to yield a cell line which produces T3/RCC bispecific antibody for targeting cytotoxic T cells to RCC.
  • Bispecific antibodies can also be produced as heteroantibodies by chemically coupling two antibodies of desired specificity.
  • Unfixed or acetone fixed cells grown on glass were examined for the presence of G 250 antigen by immunofluorescence. Undiluted culture medium was used as first step and GAM-FITC as second antibody. The cells were examined in a Leitz Orthoplan immuno- fluorescence microscope with Ploemopak.
  • EXAMPLE 8 Test Set Of Poorly Differentiated Malignant Tumors For Which The Diagnosis Of RCC Had Been Considered
  • Tumors of this test set included three cytological aspirates which present additional diagnostic difficulties, and poorly differentiated malignant tumors with a histological appearance and clinical presentation that mimicked RCC.
  • the pos ⁇ sibility of RCC had therefore been considered by the pathologist in the differential diagnosis.
  • the histological appearance of these cases included adenocarcinoma with clear cell, cribriform or acinar patterns, undifferentiated large-cell malignant tumors and spindle cell malignant tumors. None of these cases were included in the series of tumors used to test the specificity of the Mabs.
  • RC 38 stained the surface of the epithelium of the jejunum and colon, the mucous cells of the faveolar and glandular layer of the stomach ucosa and acini of sweat glands. In addition sinusoidal lining cells in the liver and lymph nodes were stained. Other tissues tested were negative (Table 3) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Sont décrits des antigènes associés au carcinome des cellules rénales (RCC). Les antigènes sont présents sur les cellules du carcinome rénal et, en quantités variables, sur d'autres tumeurs bénignes et malignes et sur des cellules normales. Sont également décrites des compositions contenant un anticorps contre un antigène ou un mélange d'anticorps, ainsi que leur utilisation dans la thérapie et le diagnostic du RCC.
PCT/US1988/001511 1987-05-06 1988-05-05 Anticorps monoclonaux contre le carcinome des cellules renales WO1988008854A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4719287A 1987-05-06 1987-05-06
US047,192 1987-05-06

Publications (1)

Publication Number Publication Date
WO1988008854A1 true WO1988008854A1 (fr) 1988-11-17

Family

ID=21947563

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/001511 WO1988008854A1 (fr) 1987-05-06 1988-05-05 Anticorps monoclonaux contre le carcinome des cellules renales

Country Status (2)

Country Link
EP (1) EP0366707A1 (fr)
WO (1) WO1988008854A1 (fr)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006871A1 (fr) * 1996-08-13 1998-02-19 Cancer Research Campaign Technology Limited Substances et procedes concernant le diagnostic et le traitement prophylactique et therapeutique du carcinome papillaire renal
US5955075A (en) * 1992-03-11 1999-09-21 Institute Of Virology, Slovak Academy Of Sciences Method of inhibiting tumor growth using antibodies to MN protein
US5972353A (en) * 1992-03-11 1999-10-26 Institute Of Virology, Slovak Academy Of Sciences MN proteins, polypeptides, fusion proteins and fusion polypeptides
US5981711A (en) * 1992-03-11 1999-11-09 Institute Of Virology, Slovak Academy Of Sciences MN-specific antibodies and hybridomas
US5989838A (en) * 1992-03-11 1999-11-23 Institute Of Virology, Slovak Academy Of Sciences Immunological methods of detecting MN proteins and MN polypeptides
US6004535A (en) * 1992-03-11 1999-12-21 Institute Of Virology, Slovak Academy Of Sciences Methods of imaging neoplastic disease and of detecting and quantifying MN protein/polypeptide using MN-specific antibodies
US6027887A (en) * 1992-03-11 2000-02-22 Institute Of Virology, Solvak Academy Of Sciences MN gene and protein
US6069242A (en) * 1992-03-11 2000-05-30 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6093548A (en) * 1992-03-11 2000-07-25 Institute Of Virology, Slovak Academy Of Sciences Detection and quantitation of MN-specific antibodies.
WO2000067792A1 (fr) * 1999-05-10 2000-11-16 Centre National De La Recherche Scientifique (Cnrs) Anticorps monoclonal dirige contre les cellules de carcinome renal humain
WO2000067697A2 (fr) * 1999-05-10 2000-11-16 Centre National De La Recherche Scientifique (Cnrs) Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
US6204370B1 (en) 1992-03-11 2001-03-20 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6297041B1 (en) 1992-03-11 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6297051B1 (en) 1997-01-24 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
WO2002063010A2 (fr) * 2001-02-07 2002-08-15 Wilex Ag Procede pour produire des anticorps recombines
WO2003068924A2 (fr) 2002-02-13 2003-08-21 Ludwig Institute For Cancer Research Proteines de fusion d'anticorps specifiques humanises g250 et leurs applications
US6774117B1 (en) 1992-03-11 2004-08-10 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
EP1461082A2 (fr) * 2001-12-03 2004-09-29 Abgenix, Inc. Anticorps contre l'antigene tumoral de l'anhydrase carbonique ix (ca ix)
EP1733736A2 (fr) 2001-02-07 2006-12-20 Wilex AG Procédé de production des anticorps recombinants contre des tumeurs
JP2008505143A (ja) * 2004-07-02 2008-02-21 ヴィレックス アクチェンゲゼルシャフト Ｇ２５０発現腫瘍の改善されたアジュバント療法
US7713704B1 (en) 1998-10-23 2010-05-11 Institute Of Virology Of The Slovak Academy Of Science MN gene and protein
US7851455B2 (en) 2001-12-13 2010-12-14 Harris Adrian L MN gene and protein
US7910691B2 (en) 1999-10-22 2011-03-22 Institute Of Virology Of The Slovak Academy Of Sciences MN gene and protein
WO2014128258A1 (fr) 2013-02-22 2014-08-28 Wilex Ag Traitement du cancer basé sur une stratification caix
US8828381B2 (en) 2002-07-01 2014-09-09 Wilex Ag Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas
US9605075B2 (en) 2001-02-07 2017-03-28 Wilex Ag Hybridoma cell line G250 and its use for producing monoclonal antibodies
US10487153B2 (en) 2015-06-10 2019-11-26 National Research Council Of Canada Carbonic anhydrase IX-specific antibodies and uses thereof
CN111732660A (zh) * 2020-07-31 2020-10-02 北京广未生物科技有限公司 骨髓间充质干细胞和单克隆抗体联合治疗癌症
US11834506B2 (en) 2017-02-08 2023-12-05 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
US11884732B2 (en) 2017-02-20 2024-01-30 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US12129300B2 (en) 2023-11-03 2024-10-29 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0119528A2 (fr) * 1983-03-11 1984-09-26 Sloan-Kettering Institute For Cancer Research Anticorps monoclonaux contre les antigènes du cancer du rein humain et procédé
EP0160250A2 (fr) * 1984-05-04 1985-11-06 Sloan-Kettering Institute For Cancer Research Panneau d'anticorps monoclonaux pour le diagnostic précoce et la thérapie du carcinome rénal
EP0210970A2 (fr) * 1985-07-25 1987-02-04 The Regents Of The University Of Minnesota Détection, visualisation et thérapie de carcinomes de cellules rénales utilisant des anticorps monoclonaux

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0119528A2 (fr) * 1983-03-11 1984-09-26 Sloan-Kettering Institute For Cancer Research Anticorps monoclonaux contre les antigènes du cancer du rein humain et procédé
EP0160250A2 (fr) * 1984-05-04 1985-11-06 Sloan-Kettering Institute For Cancer Research Panneau d'anticorps monoclonaux pour le diagnostic précoce et la thérapie du carcinome rénal
EP0210970A2 (fr) * 1985-07-25 1987-02-04 The Regents Of The University Of Minnesota Détection, visualisation et thérapie de carcinomes de cellules rénales utilisant des anticorps monoclonaux

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Biological Abstracts, vol. 80, 1985 (Philadelphia, PA, US), T.D. Moon et al.: "A highly restricted antigen for renal cell carcinoma defined by a monoclonal antibody", abstract no. 51329, & Hybridoma 4(2): 163-1172, 1985 *
Biological Abstracts, vol. 83, 1987 (Philadelphia, PA, US), E. Oosterwijk et al.: "Monoclonal antibody G-250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney", abstract no. 25749, & Int J Cancer 38(4): 489-494, 1986 *
Chemical Abstracs, vol. 105, 1986 (Columbus, Ohio, US), S.J. Luner et al.: "Monoclonal antibodies to kidney and tumor-associated surface antigens of human renal cell carcinoma", see page 462 *
Chemical Abstracts, vol. 104, 1986 (Columbus, Ohio, US), R.L. Vessella et al.: "Monoclonal antibodies to human renal cell carcinoma: recognition of shared and restricted tissue antigens", see page 385 *

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8759493B2 (en) 1992-03-11 2014-06-24 Institute Of Virology Slovak Academy Of Sciences MN gene and protein
US5989838A (en) * 1992-03-11 1999-11-23 Institute Of Virology, Slovak Academy Of Sciences Immunological methods of detecting MN proteins and MN polypeptides
US6770438B2 (en) 1992-03-11 2004-08-03 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US7816496B2 (en) 1992-03-11 2010-10-19 Institute Of Virology Of The Slovak Academy Of Sciences MN gene and protein
US8012707B2 (en) 1992-03-11 2011-09-06 Institute Of Virology Of The Slovak Academy Of Sciences MN gene and protein
US6004535A (en) * 1992-03-11 1999-12-21 Institute Of Virology, Slovak Academy Of Sciences Methods of imaging neoplastic disease and of detecting and quantifying MN protein/polypeptide using MN-specific antibodies
US6027887A (en) * 1992-03-11 2000-02-22 Institute Of Virology, Solvak Academy Of Sciences MN gene and protein
US6051226A (en) * 1992-03-11 2000-04-18 Institute Of Virology, Slovak Academy Of Sciences MN-specific antibodies and their use in cancer treatment
US6069242A (en) * 1992-03-11 2000-05-30 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6093548A (en) * 1992-03-11 2000-07-25 Institute Of Virology, Slovak Academy Of Sciences Detection and quantitation of MN-specific antibodies.
US5972353A (en) * 1992-03-11 1999-10-26 Institute Of Virology, Slovak Academy Of Sciences MN proteins, polypeptides, fusion proteins and fusion polypeptides
US5955075A (en) * 1992-03-11 1999-09-21 Institute Of Virology, Slovak Academy Of Sciences Method of inhibiting tumor growth using antibodies to MN protein
US5981711A (en) * 1992-03-11 1999-11-09 Institute Of Virology, Slovak Academy Of Sciences MN-specific antibodies and hybridomas
US6774117B1 (en) 1992-03-11 2004-08-10 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6204370B1 (en) 1992-03-11 2001-03-20 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US7186514B2 (en) 1992-03-11 2007-03-06 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6297041B1 (en) 1992-03-11 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US7115715B2 (en) 1992-03-11 2006-10-03 Institute Of Virology Slovak Academy Of Sciences Anti-idiotype antibodies to MN proteins and MN polypeptides
WO1998006871A1 (fr) * 1996-08-13 1998-02-19 Cancer Research Campaign Technology Limited Substances et procedes concernant le diagnostic et le traitement prophylactique et therapeutique du carcinome papillaire renal
US6297051B1 (en) 1997-01-24 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US7713704B1 (en) 1998-10-23 2010-05-11 Institute Of Virology Of The Slovak Academy Of Science MN gene and protein
US7074613B1 (en) 1999-05-10 2006-07-11 Centre National De La Rechershe Scientifique Monoclonal antibody directed against cells of human renal cell carcinoma
WO2000067697A3 (fr) * 1999-05-10 2001-06-28 Centre Nat Rech Scient Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
FR2793414A1 (fr) * 1999-05-10 2000-11-17 Centre Nat Rech Scient Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
JP2002543811A (ja) * 1999-05-10 2002-12-24 サントル・ナシオナル・ドゥ・ラ・ルシェルシュ・シアンティフィク ヒト腎細胞がんの細胞に対するモノクローナル抗体
FR2793497A1 (fr) * 1999-05-10 2000-11-17 Centre Nat Rech Scient Anticorps monoclonal dirige contre les cellules de carcinome renal humain
AU781426B2 (en) * 1999-05-10 2005-05-26 Centre National De La Recherche Scientifique (Cnrs) Monoclonal antibody directed against cells of human renal cell carcinoma
WO2000067697A2 (fr) * 1999-05-10 2000-11-16 Centre National De La Recherche Scientifique (Cnrs) Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
WO2000067792A1 (fr) * 1999-05-10 2000-11-16 Centre National De La Recherche Scientifique (Cnrs) Anticorps monoclonal dirige contre les cellules de carcinome renal humain
US7910691B2 (en) 1999-10-22 2011-03-22 Institute Of Virology Of The Slovak Academy Of Sciences MN gene and protein
WO2002062972A3 (fr) * 2001-02-07 2002-12-12 Wilex Ag Lignee de cellules d'hybridomes g250 et son utilisation pour produire des anticorps monoclonaux
EP1733736A2 (fr) 2001-02-07 2006-12-20 Wilex AG Procédé de production des anticorps recombinants contre des tumeurs
WO2002063010A2 (fr) * 2001-02-07 2002-08-15 Wilex Ag Procede pour produire des anticorps recombines
US9605075B2 (en) 2001-02-07 2017-03-28 Wilex Ag Hybridoma cell line G250 and its use for producing monoclonal antibodies
WO2002062972A2 (fr) * 2001-02-07 2002-08-15 Wilex Ag Lignee de cellules d'hybridomes g250 et son utilisation pour produire des anticorps monoclonaux
WO2002063010A3 (fr) * 2001-02-07 2003-11-27 Wilex Ag Procede pour produire des anticorps recombines
EP1461082A2 (fr) * 2001-12-03 2004-09-29 Abgenix, Inc. Anticorps contre l'antigene tumoral de l'anhydrase carbonique ix (ca ix)
US7378091B2 (en) 2001-12-03 2008-05-27 Amgen Fremont Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
EP1461082A4 (fr) * 2001-12-03 2006-06-28 Abgenix Inc Anticorps contre l'antigene tumoral de l'anhydrase carbonique ix (ca ix)
US7855185B2 (en) 2001-12-13 2010-12-21 Institute Of Virology Of The Slovak Academy Of Sciences MN gene and protein
US8334137B2 (en) 2001-12-13 2012-12-18 Bayer Healthcare Llc MN gene and protein
US7851455B2 (en) 2001-12-13 2010-12-14 Harris Adrian L MN gene and protein
US7910549B2 (en) 2001-12-13 2011-03-22 Institute Of Virology Of The Slovak Academy Of Sciences MN gene and protein
WO2003068924A2 (fr) 2002-02-13 2003-08-21 Ludwig Institute For Cancer Research Proteines de fusion d'anticorps specifiques humanises g250 et leurs applications
US8828381B2 (en) 2002-07-01 2014-09-09 Wilex Ag Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas
EP2497497A1 (fr) 2004-07-02 2012-09-12 Wilex AG Therapie adjuvante ameliorée des tumeurs exprimant G250
JP2008505143A (ja) * 2004-07-02 2008-02-21 ヴィレックス アクチェンゲゼルシャフト Ｇ２５０発現腫瘍の改善されたアジュバント療法
US10620208B2 (en) 2013-02-22 2020-04-14 Wilex Ag Classifying a cancer disease using CAIX expression
WO2014128258A1 (fr) 2013-02-22 2014-08-28 Wilex Ag Traitement du cancer basé sur une stratification caix
US10487153B2 (en) 2015-06-10 2019-11-26 National Research Council Of Canada Carbonic anhydrase IX-specific antibodies and uses thereof
US11834506B2 (en) 2017-02-08 2023-12-05 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
US11884732B2 (en) 2017-02-20 2024-01-30 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US11939384B1 (en) 2018-02-08 2024-03-26 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
CN111732660A (zh) * 2020-07-31 2020-10-02 北京广未生物科技有限公司 骨髓间充质干细胞和单克隆抗体联合治疗癌症
US12129300B2 (en) 2023-11-03 2024-10-29 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor

Also Published As

Publication number Publication date
EP0366707A1 (fr) 1990-05-09

Similar Documents

Publication Publication Date Title
WO1988008854A1 (fr) Anticorps monoclonaux contre le carcinome des cellules renales
Welt et al. Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33.
CA1338706C (fr) Anticorps monoclonaux anti-cancer du sein chez la femme; leur utilisation pour visualiser ce type de cancer
Oosterwdk et al. Monoclonal antibody G 250 recognizes a determinant present in renal‐cell carcinoma and absent from normal kidney
EP0394277B1 (fr) Anticorps monoclonaux de seconde generation ayant une specificite de liaison sur tag-72 et des carcinomes humains, et procede d'utilisation de ces anticorps
US4724213A (en) Murine hybridoma Lym-1 and diagnostic antibody produced thereby
Wynant et al. Immunoscintigraphy of prostatic cancer: preliminary results with 111In‐labeled monoclonal antibody 7E11‐C5. 3 (CYT‐356)
US5153118A (en) Monoclonal antibodies having binding specificity to human prostate tumor-associated antigens and methods for employing the same
JPH0564130B2 (fr)
Stein et al. Murine monoclonal antibodies raised against human non-small cell carcinoma of the lung: specificity and tumor targeting
JPS6242935A (ja) 臓器造影剤組成物
EP1871810A2 (fr) Anticorps anti-psma conjugués
JP2574269B2 (ja) ヒト前立腺腫瘍関連抗原に対する結合特異性を有するモノクロ−ナル抗体類およびそれらを使用する方法
Babaian et al. Radioimmunoscintigraphy of prostate cancer
US5084266A (en) Method for tumor imaging utilizing a labelled tumor specific antibody and a non-tumor reactive antibody
Gasparini et al. Tumor imaging of colo‐rectal carcinoma with an anti‐CEA monoclonal antibody
Griffin et al. Initial clinical study of indium-111-labeled clone 110 anticarcinoembryonic antigen antibody in patients with colorectal cancer.
US5250297A (en) Tumor-associated antigen, antibodies, compositions and uses therefor
AU4415100A (en) Monoclonal antibody directed against cells of human renal cell carcinoma
Dienhart et al. Imaging of non-small cell lung cancers with a monoclonal antibody, KC-4G3, which recognizes a human milk fat globule antigen
Britton et al. Radioimmunoscintigraphy
JPH03188099A (ja) 新規な腫瘍関連抗原
Hanabata et al. Immunohistochemical study on hepatic tumors--KM01 stains compared with AFP, CEA, CA19-9 and RAS P21.
EP0473651A1 (fr) Anticorps monoclonaux reconnaissant les cellules malignes provenant de carcinomes cystiques
AU625856B2 (en) Second generation monoclonal antibodies having binding specificity to tag-72 and human carcinomas and methods for employing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1988906254

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1988906254

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1988906254

Country of ref document: EP